Projects and Initiatives on Personalised Medicine

This list of projects and initiatives in personalised medicine is the output of a mapping activity that has involved all EP PerMed partners in a collective endeavour and represents a step forward in the rationalisation of initiatives on PM that are being carried out in the member states.

This list has a dual purpose: on one hand it provides an up-to-date snapshot of the landscape of personalised medicine initiatives, and on the other it will be used by the whole partnership as tool for outreach and cooperation activities. Furthermore, the list will be useful to spot and select the key players, i.e. initiatives that are setting the gold standard in personalised medicine development. EP PerMed and its network can support and help these initiatives thrive, also inviting them to take part to the calls for Best Practice.

Download as Excel file (XLSX)

Name	Sponsor/Funding Agency	Country	Region (if applicable)	Start year	End year	Keywords	Area of interest	Health category (according to HRCS)	Overall goal/mission
GENOMED4ALL	EC	Multiple countries	Not applicable	2021	2025	blood cancers: AI	Artificial Intelligence;	Blood;Cancer and neoplasms	https://genomed4all.eu/about/
OncoCare@Home	VLAIO	Belgium	Flanders	2021	2024	Health data, remote monitoring	Personalized care at home	Cancer	reduce hospital admissions with 10% and significantly improve life expectancy and quality of life
ACCN Austrian Comprehensive Cancer Network	Austrian Ministry of Education, Science and Research	Austria	National	2024	ongoing	network, comprehensive cancer centers, outreach, research, clinical trials,	Cancer	Cancer and neoplasms	The Austrian Comprehensive Cancer Network (ACCN) pools the resources and expertise of the three Austrian CCCs in Graz, Vienna and Innsbruck in order to jointly develop innovative treatment approaches and research results for cancer patients. The aim of the ACCN is to further improve prevention and cutting-edge medicine in oncology through the networking of local structures and to make optimum use of synergies between the three locations in order to fight cancer together.
CD-Labor of imaging and evidence based precision radiation therapy	Christian Doppler Forschungsgesellschaft	Austria	Vienna	2024	2030	Radio-oncological treatments	Cancer	Cancer and neoplasms	The aim of this CD Laboratory is to improve radio-oncological treatments, i.e. the irradiation of tumours by combining new technical approaches in (real-time) imaging, tumour-biologically oriented adaptive treatment concepts and automated prospective data acquisition in order to be able to offer all patients individualised therapy.
CD-Labor of patient centric imaging for breast cancer screening	Christian Doppler Forschungsgesellschaft	Austria	Vienna	2024	2031	Breast cancer, Cd-Labor	Cancer	Cancer and neoplasms	The mission of this CD laboratory is to develop and apply technological innovations to establish Triple S (soft, safe, and smart) breast imaging. The CD Laboratory addresses the unmet need for patient-centered breast imaging that will lead to improved patient acceptance and participation in breast imaging to improve health outcomes.
BRIGHT	European Commission via EIT Health BRIGHT innovation activity	Estonia	Not applicable	2022	ongoing	genetic-risks, breast cancer, screening, healthcare	genetic-risks, breast cancer, screening, healthcare	Cancer and neoplasms	The BRIGHT project team is working on the implementation of a genetics-based test for breast cancer risk, to identify those who would benefit from targeted breast cancer screening.
MyPeBs	French government and European Union’s Horizon 2020 research and innovation programme	France	Not applicable	2020	2025	Cancer	Cancer	Cancer and neoplasms	MyPeBS is an international EU-funded clinical study that evaluates a new breast cancer screening strategy
IHU PRISM	institut Gustave Roussy	France	Paris	–	ongoing	Cancer	Cancer	Cancer and neoplasms	ultra personalisation of the care
CCC-Netzwerk onkologischer Spitzenzentren	German Governement	Germany	National	–	ongoing	oncology	oncology	Cancer and neoplasms	The organization promotes centers of excellence in cancer medicine throughout Germany
DNPM, Deutsches Netzwerk für Personalisierte Medizin	G-BA	Germany	National	–	ongoing	personalised medicine	personalised medicine	Cancer and neoplasms	The aim of the project is to set up corresponding centers for personalized medicine at a further nine locations nationwide together with the national university cancer centers, the Comprehensive Cancer Centers (CCCs), and to bundle the competencies in a German Network for Personalized Medicine (DNPM).
FBREK-Zentren, Deutsches Konsortium Familiärer Brust- und Eierstockkrebs	German Governement	Germany	National	–	ongoing	breast and ovary cancer	Can cer	Cancer and neoplasms	The centres in the German Consortium for Familial Breast and Ovarian Cancer offer advice and support to those seeking advice from a high-risk family who have a family history of breast and/or ovarian cancer.
Haus der Krebsselbsthilfe	German Cancer Aid	Germany	National	–	ongoing	patient organisation oncology	Patient oncology	Cancer and neoplasms	The House of Cancer Self-Help – Federal Association (HKSH-BV) is the umbrella organisation of eleven federal associations of cancer self-help with a total of around 1,500 self-help groups. They provide comprehensive and independent information on the various types of cancer and how to cope with the disease. They offer contact points on site, on the phone or in forums for an exchange beyond the doctor’s consultation.
NCT/DKTK-MASTER	–	Germany	National	–	–	translational oncology research	Cancer, Genomics	Cancer and neoplasms
nNGM, nationalen Netzwerk Genomische Medizin (nNGM) Lungenkrebs	Deutsche Krebshilfe	Germany	National	2018	ongoing	lung cancer	Can cer	Cancer and neoplasms	To improve the prognosis (better survival with better quality of life) of patients with advanced lung cancer in Germany.
ONCOnnect Programm	Else-Kröner-Fresenius Stiftung	Germany	National	–	–	personalised oncology	personalised medicine	Cancer and neoplasms	The Else Kröner Medical Scientist Kolleg ONCOnnect focuses on new therapies and diagnostic instruments in the field of personalized oncology
PM4Onco	BMBF	Germany	National	2023	2027	personalised oncology	personalised medicine	Cancer and neoplasms	The aim of the cross-consortium PM4Onco use case is to develop solutions for an interoperable infrastructure for the integration and sharing of clinical and biomedical data in molecular tumor boards.
EUCAIM: EUROPEAN FEDERATION FOR CANCER IMAGES	European Union	Multiple countries	Not applicable	2023	2026	Artificial Intelligence;Big Data;	Artificial Intelligence;Big Data;	Cancer and neoplasms	The EUropean Federation for CAncer IMages (EUCAIM) is a part of the European Commission-initiated European Cancer Imaging Initiative, which aims to foster innovation and deployment of digital technologies in cancer treatment and care to achieve more precise and faster clinical decision making, diagnostics, treatment and predictive medicine for cancer patients.
Norwegian Cancer Precision Medicine Implementation Consortium; CONNECT	public-private consortium	Norway	National	2020	ongoing	Personalised Medicine	Personalised Medicine	Cancer and neoplasms	CONNECT is a public-private consortium driving the implementation of precision cancer medicine by jointly addressing key obstacles and piloting novel solutions to transform the current practice. The consortium has been initiated by 22 founding partners in December 2020, attracted multiple additional partners since then and is coordinated by Oslo Cancer Cluster. CONNECT gathers all Norwegian university hospitals, pharmaceutical and technology companies, the Norwegian Cancer Society as a patient organisation, the Norwegian Institute of Public Health, the Norwegian Directorate of Health, and the Norwegian Medicines Agency. The consortium is open to include new partners from the industry and public sector.
Prime-Rose Norway	EU grant	Norway	Not applicable	2023	2028	Cancer	Cancer	Cancer and neoplasms	PRIME-ROSE clinical trials target refractory cancer patients who have an advanced malignancy and are progressing on standard treatment, but with sufficient quality of health to anticipate benefit from another line of treatment.
Joint Action Implementation of cancer screening programmes (EUCanScreen)	European Health and Digital Executive Agency (HADEA)	Spain	Basque Country	2024	2028	Cancer screening, implementation, governance, sustainability, equity, cost-effectiveness, data sharing, capacity-building, personalized, new approaches, artificial intelligence, EHDS	Implementation of evidence-based and cost-effective screening programmes for breast, cervical and colorectal cancers; Program governance and sustainability; Data collection and monitoring of screening programmes; Reducing cancer inequalities; Capacity building in cancer screening and Collaboration and coherence with related projects funded under EU Programmes.	Cancer and neoplasms	The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancer as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
Joint Action on Networks of Expertise (JANE) (101075328)	European Health and Digital Executive Agency (HADEA)	Spain	Basque Country	2022	2024	Cancer, networks of expertise, omics, high-tech, palliative care, survivorship, prevention	personalized primary prevention; survivorship; palliative care; omic technologies; hi-tech medical resources; one ormore complex & poor-prognosis cancer(s); adolescents and young adults (15-39 years at cancer diagnosis) with cancer.	Cancer and neoplasms	The Joint Action will have two goals: 1) to prepare everything necessary to launch the new Networks of Expertise; and 2) to critically evaluate existing models of current and future EU networking with a view to optimizing the functioning of the new Networks of Expertise. The project’s management goal is to bring about the preaparation of the creation of 7 Networks of Expertise in the cancer field in the following domains: personalized primary prevention; survivorship; palliative care; omic technologies; hi-tech medical resources; one or more complex & poor-prognosis cancer(s); adolescents and young adults (15-39 years at cancer diagnosis) with cancer.
Ludwig Boltzmann Institut of hematology and oncology	Ludwig Boltzmann Gesellschaft	Austria	Vienna	2008	ongoing	Hematology, Oncology	Cancer, Leukemia	Cancer and neoplasms; Blood	The overarching goal of the Ludwig Boltzmann Institute for Hematology and Oncology (formerly Ludwig Boltzmann Cluster Oncology (LBC ONC)) is to develop new therapeutic concepts in cancer research aiming at eliminating cancer stem cells in leukemias and solid tumors.
AT MP Wal	SPW EER	Belgium	Wallonia	2024	2027	Drug and biomarkers discovery;	Drug and biomarkers discovery;	Cancer and neoplasms;Blood;Inflammatory and immune system;Renal and urogenital;Respiratory;Generic health relevance relevance;	The ATMP PIT is intended to provide a major stimulus to Wallonia’s advanced therapy medicines sector, by establishing new partnerships between academia (including teaching hospitals), a research center and businesses of every size. These various work packages cover all the links in the ATMP value chain and address particular areas of scientific research with high development potential, various aspects of preclinical and clinical research, and innovative approaches to production process design and control. The project will bring with it a substantial increase in the number of researchers and technicians working in this sector. Estimates predict that more than 470 direct jobs and 1,200 indirect jobs will be created over the next five years.
NAGEN program	CFN/EU	Spain	Navarra	2016	ongoing	Big Data;Biobanking;Drug and biomarkers discovery;Omic sciences;	Big Data;Biobanking;Drug and biomarkers discovery;Omic sciences;	Cancer and neoplasms;Cardiovascular;Congenital disorders;Metabolic and endocrine;Generic health relevance	The NAGEN Program is a strategic initiative to implement genome analysis in clinical practice of the Navarre Health Service.
Integrated Personalised Medicine Strategy for Navarre	CFN	Spain	Navarra	2017	ongoing	Personalised medicine	Big Data;Policy ;	Cancer and neoplasms;Cardiovascular;Generic health relevance	improve the healthcare we provide to citizens. Bringing science, technology, and the laboratory even closer to clinical practice, to the healthcare we receive from healthcare professionals.
National Center for Gene Therapy and Drugs based on RNA Technology	Ministry of University and Research	Italy	National	2022	2025	Gene Therapy and Drugs, RNA Technology	Drug and biomarkers discovery;Gene Therapy and therapy based on RNA Technology;	Cancer and neoplasms;Cardiovascular;Inflammatory and immune system;Infection;Metabolic and Endocrine endocrine;Neurological;genetic diseases;	Two main goals: increasing the technological know-how necessary to design and deliver RNA-based and gene therapy medicinal products and identifying promising candidate drugs/genes in five major areas of human diseases (genetic diseases, cancer, metabolic/cardiovascular diseases, neurodegenerative disorders and inflammatory/infectious diseases).
Heal Italia (Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine)	Ministry of University and Research	Italy	National	2022	2025	Personalised medicine	Cancer and neoplasms;Metabolic and endocrine;Cardiovascular;rare diseases;	Cancer and neoplasms;Metabolic and endocrine;Cardiovascular;rare diseases;	The overall objective is to provide new, cost-effective and evidence-based predictive and non-invasive diagnostic pathways for faster, earlier, more precise, accessible and economical prediction, detection and monitoring of monogenic (rare) diseases, polygenic (cardiovascular and metabolic) and cancer, as well as to identify innovative and effective therapeutic approaches. The project also aims to identify and reduce inequalities (extremely large between Northern and Southern Italy) by developing an interregional collaboration roadmap to define evidence-based pathways that can be easily used in clinical practice. The Mission is to facilitate the transition towards efficient methods and tools in terms of costs and time, which allow early diagnosis and frequent screening of patients, two of the cornerstones of approaches to precision medicine.
P4Health (101136375)	European Commision	Poland	National	2024	2030	Biobanking, Precise Phenotyping, Precision Medicine	Biobanking, Precise Phenotyping, Precision Medicine	Cancer and neoplasms;Neurological	Establishment of a Center of Excellence in Precision Medicine.
Clinical Research Group: Austrian digital heart programme	Ludwig Boltzmann Gesellschaft	Austria	Innsbruck	2023	2031	smart phones and diagnostics of cardial arrythmic event	Digital, screening	Cardiovascular	Digital Medicine for Population-Wide Atrial Fibrillation Screening and Treatment
Ludwig Boltzmann Institut of cardiovascular research	Ludwig Boltzmann Gesellschaft	Austria	Vienna	1960s	ongoing	–	Therapies, Cardiovascular diseases	Cardiovascular	The Ludwig-Boltzmann-Institute for Cardiovascular Research focuses on interdisciplinary research of therapies for cardiovascular diseases.
Genoma Puglia. Programma di ricerca per la diagnosi precoce e la cura delle malattie rare su base genetica	Regione Puglia	Italy	Puglia	2023	ongoing	Genomics	Biobanking	Congenital disorders;Reproductive health and childbirth	Newborn screening programme
CD-Labor of Machine Learning and Precision Imaging	Christian Doppler Forschungsgesellschaft	Austria	Vienna	2023	2029	Radiology, lung cancer, treatments	Cancer	Generic health relevance	This CD Laboratory will integrate radiological and pathological images as well as molecular data using new machine learning methods.
ÖPPM – Austrian Platform for Personalised Medicine	Austrian Ministry of Education, Science and Research, several funding agencies and member fees	Austria	National	2017	ongoing	Platform, network, outreach, personalized medicine	Personalised Medicine	Generic health relevance	The Austrian Platform for Personalized Medicine (ÖPPM) is dedicated to this challenge and is aimed at all interested parties and stakeholders who want to contribute to the research and implementation of personalized medicine in Austria. A primary goal of the PPP is the networking of all stakeholders across disciplinary and sectoral boundaries in order to advance the discussion of the topic of personalised medicine in Austria, in the European and in the international context through increased strategic cooperation.
RENUBIA	BMG	Germany	National	2021	2026	project on big data and omics and regulation	Big data, omics, regulation	Generic health relevance	The aim is to establish new procedures that can be used to deal with regulatory issues in connection with “OMICS” methods even better in the future.
GoGreece (Genome of Greece)	EC and private ones	Greece	Not applicable	2010	ongoing	genetics, genomics, infrastructure, data, personalised medicine	Big Data	Generic health relevance	See https://gogreece.org.gr/
National Genetics and Genomics Office	Irish Government	Ireland	Not applicable	2023	ongoing	Genomics	Other	Generic health relevance	The NGGO is responsible for coordinating a national approach to genetics and genomics, supporting the development of a skilled genetic and genomic workforce, enhancing clinical services for patients and families, and strengthening laboratory and data infrastructure to drive advances in genetic and genomic medicine services.
Rare Disease Clinical Trials Network	Health Research Board (HRB)	Ireland	National	2022	2027	Rare Diseases, Training, Network, PPI, Trials, Research	Rare diseases	Generic health relevance	HRB-funded clinical trial network for development of rare disease trials, methodology and researcher training; FOR and WITH patients and their families.
Rare Disease Research Catalyst Consortium	Health Research Board (HRB)	Ireland	National	2023	2026	Rare Diseases, Network, PPI, Trials, Research, ERN	Generic Health Relvanc	Generic health relevance	This RD Research Catalyst Consortium brings together Irish ERN Clinical leads, researchers and patients/advocates to increase RD research in Ireland and ready Irish RD infrastructure to enter RD Partnership at launch.
EHAB	HORIZON EUROPE	Multiple countries	EHAB is endorsed by several regional and European level organisations, including : the Province of North-Brabant, the Province of Limburg, the RegMed XB consortium, the department of Economy, Science and Innovation of the Flemish Government, the Smart Health Pilot of the Vanguard Initiative, the Health Department from the Generalitat de Catalunya, Leitat, ASEBIO, the Vall d’Hebron Institute of Oncology, the Fraunhofer-Institut für Produktionstechnik und Automatisierung (Fraunhofer IPA), and the Marshall Office of the Silesia Voivodeship.	2024	2024	Regenerative medicine, biomaterials, network	Regenerative medicine, biomaterials	Generic health relevance	Developing the European ATMP value chain
National consortium for sequencing and personalized	RCN	Norway	Mix of national and south-East regional	–	ongoing	Personalised Medicine	Personalised Medicine	Generic health relevance
Estratégia Nacional para a Medicina Genómica (PT_MedGen)	FCT \| AICIB \| INSA	Portugal	National	2020	2024	Genomics Medicine \| National Strategy \| Portugal	Biobanking;Citizen and Patient engagement;Clinical studies;ELSA;Medical device;Policy ;	Generic health relevance	Definition of the roadmap for the planning and implementation of the Portuguese National Strategy for Genomic Medicine.
Slovenian Genome Project	Slovenian Government	Slovenia	National	2022	Ongoing	Genomics	Big Data	Generic health relevance	Slovenia’s national genome database project to characterise population variation and support rare disease diagnostics.
Personalised Medicine Center Karolinska (PMCK)	Regional and governmental funding	Sweden	Stockholm	2021	ongoing	Health care, precision medicine	Health Technology Assesment;Omic sciences;Policy ;Big Data;Artificial Intelligence;Citizen and Patient engagement;Drug and biomarkers discovery;Health care and R&I;	Generic health relevance	Precision Medicine Center Karolinska (PMCK) is a collaboration between Karolinska University Hospital and Karolinska Institutet. The mission is to create the conditions for taking precision medicine all the way into the every day clinical practise of healthcare. By finding organizational solutions for the integration of diagnostics, treatment and research, precision medicine can be moved closer to care and thus closer to the patient.
Beyond 1 Million Genomes plus (B1MGplus)	European Commission	UK	Not applicable	2025	2028	gene, genome, genotype, infrastructure	Genetic, clinical data	Generic health relevance	To create a network of genetic and clinical data across Europe
African Vaccine Regulatory Forum	–	African Continent	Not applicable	2006	ongoing	Africa, Vaccines	Other	Infection	Network of African national regulatory authorities and ethics committees that uses harmonization and reliance as pillars for capacity building. AVAREF’s mission is to help national regulatory authorities, ethics committees, and sponsors achieve consensus on ethical and regulatory questions surrounding the research and development of medical products in Africa. Its primary aim is to improve access to medical products across the continent by reducing review and approval times for clinical trial applications, while also optimizing quality of regulatory processes.
Central African Network on Tuberculosis, HIV/AIDS and Malaria	European Commission	African Continent	–	2008	ongoing	network, diseases	Clinical studies	Infection	EDCTP network of excellence for Africa central region. To build capacity in seven institutions in the three countries namely Cameroon, Gabon and the Republic of Congo (RoC) for the conduct of clinical trials.
Move Buddy	EU – I3	Belgium	Flanders	2024	2025	health data, childhood obesity, nutrition & lifestyle factors	Child health	Metabolic	Decrease childhood obesity & provide personalized care
INTERVENE: International consortium for integrative genomics prediction	European Union’s Horizon 2020 research and innovation programme	Multiple countries	Nota applicable	2021	2026	Big Data;Artificial Intelligence;Omic sciences;Biobanking;Clinical studies;	Big Data;Artificial Intelligence;Omic sciences;Biobanking;Clinical studies;	Metabolic and endocrine;Cardiovascular;Cancer and neoplasms	The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. Resulting in unprecedented potential for prediction, diagnosis, and personalised treatments for complex and rare diseases. Some of the largest biobanks in Europe and two in the USA will be securely linked and harmonized in a GDPR-compliant repository with data from more than 1.7 million genomes.
Innovative Health Initiative (IHI)	EC and private companies	Multiple countries	Not applicable	2021	ongoing	Funding	Policy	Not aplicable	To translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involves diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to healthcare, covering prevention, diagnosis, treatment, and disease management.
SUSA (Sustainable Healthcare with Digital Health Data Competence)	Co-funded by the EU and national entities	Multiple countries	Not applicable	–	ongoing	Education, health data, digitalisation	Big Data	Not aplicable	SUSA (Sustainable Healthcare with Digital Health Data Competence) is an innovative project that will introduce 46 Bachelor’s and Master’s degree programs, along with 16 lifelong learning modules. These programs are tailored to develop essential skills in digital health, artificial intelligence, data analytics, and cybersecurity, addressing the growing demands of the health sector across Europe.
COMPASS-AI	Co-funded by the EU	Multiple countries	–	2025	2029	artificial intelligence, AI, health data	Artificial Intelligence	Not aplicable	To overcome critical barriers to the safe and effective deployment of AI in healthcare by developing scalable, equitable solutions, with a focus on cancer care and remote regions
African BioGenome Project	Private and public authorities	African Continent	Not applicable	2021	ongoing	Africa, Genomics	Big Data	Not applicable	A coordinated pan-African effort to build capacity (and infrastructure) to generate, analyze and deploy genomics data for the improvement and sustainable use of biodiversity and agriculture across Africa.
African Population Cohort Consortium (APCC)	Welcome Trust	African Continent	Not applicable	2022	ongoing	Africa, network	Data management, Innovation, Training	Not applicable	To create a forum on population cohorts that brings together a broad spectrum of African scientists, policymakers, and research communities to co-create and build enthusiasm and support for an inclusive consortium of all longitudinal and population-based research cohorts in Africa
DS-I Africa (The Data Science for Health Discovery and Innovation in Africa	NIH Common Fund	African Continent	–	2020	ongoing	Data science	Data management, Innovation, Training	Not applicable	S-I Africa) Initiative aims to leverage data science technologies to transform biomedical and behavioral research and develop solutions that would lead to improved health for individuals and populations.
Pan-Africa Bioethics Initiatives		African Continent	Not applicable	2001	ongoing	Africa, Bioethics	Clinical studies	Not applicable	Focused on the development of strong national ethical review system as well as providing regional Good Clinical Practice standards and training. The PABIN mission is directed toward building competent and independent in-country decision-making structures for health research
Pathogen Genomic Diversity Network Africa	not-for-profit association	African Continent	Not applicable	–	ongoing	Africa, Genomics	Other	Not applicable	Independent, not-for-profit African-led scientific association of researchers from across Africa, which focusses on generating, analysing and utilising pathogen genomic diversity data to improve the health and well-being of all Africans. A healthier Africa through harnessing the full potential of genomics research.
Personalized Medicine in North Africa	Coordinato dall’Institut Pasteur, e finanziato dal Ministero francese per l’Europa e gli Affari Esteri	African Continent	Not appicable	2021	2024	Personalised medicine	Other	Not applicable	International project for the development of precision medicine in Magreb. It aims to offer the patient a treatment adapted to the characteristics of his disease and his environment
Trials of Excellence in Southern Africa	EC	African Continent	–	2009	ongoing	network	Clinical studies	Not applicable	EDCTP network of excellence for Africa south region. Specific objectives: To strengthen collaboration and optimize the use of resources and infrastructure within the network To offer training and mentorship aimed to promote professional development and scientific leadership in Clinical Trials. Including data management, data analysis and sharing across the network. Strengthen South-South & North-South collaborations between researchers and institutions – focus on supporting less established institutions-. To encourage, promote networking and dialogue between researchers, communities and policy-makers to maximize the impact of Clinical Research in Africa.
Southern African Human Genome Programme	–	African Continent	–	2011	ongoing	Genomics	Biobanking	Not applicable	National and regional initiative that aims to unlock the unique genetic character of southern African populations. Its vision is to improve quality of lifeby understanding human genetic diversity.
MedTech Wallonia	SPW EER	Belgium	Wallonia	2021	2027	Medical device;	Medical device;	Not applicable	The ambition is to build a MedTech sector for Wallonia which integrates the entire value chain of product & service development as well as all major strategic players including hospitals.
MedReSyst	SPW EER + FEDER	Belgium	Wallonia	2021	2027	Artificial Intelligence;Big Data;Policy ;	Artificial Intelligence;Big Data;Policy ;	Not applicable	Technological innovation at the service of medicine. MedReSyst aims to centralise and analyse databases using several levels of artificial intelligence. From the DNA genome to environmental influences, everything is intertwined as a cause of disease. Our mission is to understand all these interactions in order to find the best way to treat as many diseases as possible.
Development of universal data model and continuity of care processes based on international standards for new generation health information systems	Norway Grants Programme “Green ICT”	Estonia	–	2021	2024	digital health care data, new generation, EHR	digital health care data, new generation, EHR	Not applicable	The aim of the Project “Development of universal data model and continuity of care processes based on international standards for new generation health information systems” is to find appropriate model for digital health care data that could be used for data collection and storage in new generation TIS with the feasibility to implement the same model in other large scale Electronic Health Records (EHR). This data model will be foundation for health care professionals to use digital decision support systems in context of Electronic Medical Record. The definition of data model would lead to the development of EHR processes where minimal set of health status summaries are defined for each specialty/health issue to make evidence-based decision possible. In turn, defined health status summaries are needed for development of continuity of care processes and training of artificial intelligence and development of intuitive Electronic Medical Records.
Nordic eHealth for Patients: Benchmarking and Developing for the Future	Estonian Research Council	Estonia	Not applicable	2021	2023	digitalization, healthcare, eHealth	digitalization, healthcare, eHealth	Not applicable	NORDeHEALTH aims to identify the challenges and opportunities in digitalization of health services, especially when national portals are implemented to give patients online access to their electronic health records (PAEHR) and increase self-management and transparency in healthcare. The goal is to enable further digitalization of the public health sector by providing concrete feedback to the national authorities in the respective countries, provide guidelines and frameworks for design, implementation and evaluation of personal eHealth services (PeHS).
DEFIDIAG	funded under the PFGM	France	National	–	–	–	–	Not applicable	Defidiag, for intellectual disability DIAGnostic, is the pilot project Rare Diseases of the Plan France Médecine Génomique 2025.
Fédération Française de Génétique Humaine	French government	France	National	–	–	Personalised Medicine, national policies	Genetics	Not applicable	This association aims to bring together the clinician geneticists physicians in order to promote the development of medical genetics in France and in French speaking countries.
Le référentiel des actes innovants hors nomenclature de biologie et d’anatomopathologie (RIHN)	French government	France	National	–	–	Biology	device and diagnostic tools	Not applicable	The reference framework for nomenclature innovative acts (RIHN), set up by the General Directorate of Healthcare Provision (DGOS) in the context of the development of health innovation, offers a long term support for innovative medical biology and pathological pathology. This «innovation support pillar» allows for an early and transient management of innovative acts in medical biology and anatomopathology.
PLAN FRANCE MÉDECINE GÉNOMIQUE 2025	French government	France	National	2015	ongoing	Personalised Medicine, national policies, genetics	Genomics	Not applicable	aims to change the way patients are diagnosed, treated and prevented by 2025.
Plan innovation santé France 2030	French government	France	National	–	2030	Personalised Medicine, national policies	Health	Not applicable	650 M euro for funding 5P medecine (Prevention, personnalized, predictive, participative, based on proof)
Réseau national de pharmacogénétique (RNPGx)	French government	France	National	–	–	Genetics, national policies	–	Not applicable	RNPGx (The French National Network of Pharmacogenetics ) recommendations for pharmacogenetic testing by genotyping
Société Française de Médecine Prédictive et Personnalisée	French government	France	National	–	–	Personalised Medicine, national policies	Personalised Medicine	Not applicable	The SFMPP contributes to good practice recommendations of innovative tests for the prevention and treatment of cancer and rare diseases.
Société Francaise de Pharmacologie et Thérapeutique (SFPT)	French government	France	National	1996	ongoing	Drugs, Therapeutics	Pharmacology, Therapeutics	Not applicable	Promote research in pharmacology and therapeutics; support drug innovation and contribute to the proper use of drugs and medical devices by improving pharmacological and therapeutic knowledge
Achse e.V	No-proft association	Germany	National	2004	ongoing	patient organisation rare diseases	–	Not applicable	It is the umbrella organisation of and for people with chronic rare diseases and their relatives in Germany. With its more than 130 patient organisations, ACHSE bundles expertise and knowledge in the field of rare diseases and represents the interests of affected people.
genomDE	BMG	Germany	National	2021	2024	+1million genomes	Genomics	Not applicable	The genomDE consortium brings together 14 of the most important nationwide initiatives in genome medicine for data use and sequencing in medicine. In addition to leading medical networks and professional societies, the patient representatives for the treatment of rare diseases and cancer operating at the federal level are also involved in the project with their special concerns.
NAMSE/Zentren für Seltene Erkrankungen; Nationalen Aktionsbündnisses für Menschen mit Seltenen Erkrankungen	–	Germany	National	–	–	rare diseases	rare diseases	Not applicable	The NAMSE is a coordination and communication body with the aim of initiating better patient care for people with rare diseases.
Genetic analyzer for whole human genome sequencing (Lithuanian genome)	Cofund: EU RRF funds (6.3 Mln Eur), national budget (1.3 Mln Eur)	Lithuania	Capital Region	2023	2026	Genome sequencing	Biobanking;Big Data;Medical device;Omic sciences;	Not applicable	To improve the availability and quality of treatment services for the ever-increasing number of patients, contributing to the smooth and efficient functioning of the implemented new model of service provision and organization, i.e. in order to ensure timely and high-quality treatment, it is necessary to expand the available infrastructure of the National Cancer Institute, Vilnius University Hospital Santaras Clinics and Lithuanian University of Health Sciences Kaunas Clinics by purchasing genetic analyzers for whole human sequencing, conducting whole human genome sequencing studies, and purchasing the necessary IT equipment. The implemented project will make it possible to create a sustainable genomic medicine network in the country for the development of future personalized medicine, the opening of genome research data and the development of future personalized medicine innovations.
Clinnova	FNR national funder	Luxembourg	Not applicable	2023	ongoing	Artificial Intelligence;Big Data;AI-driven precision medicine;	Artificial Intelligence;Big Data;AI-driven precision medicine;	Not applicable	The initiative aims to realise the benefits of precision medicine for treatment decisions through data federation, standardisation, and interoperability. The project is supported jointly by the FNR’s NCER programme, the Grand Est Region, the Canton of Basel as well as the State of Baden-Württemberg and will establish a shared launchpad for medical AI algorithm development in the heart of Europe.
PRECISEU	HORIZON EUROPE	Multiple countries	Not applicable	2024	2029	ATMP, Health Data, Innovation	Personalised Medicine	Not applicable	Its aim is to accelerate the adoption of personalized medicine in Europe.Among its main actions, the project will focus on speeding up the adoption of personalized medicine in Member States, with a particular emphasis on the use of health data and the acceleration of advanced therapies.
ICPerMed	European Commission/international partners	Multiple countries	Not applicable	2016	ongoing	Personalised Medicine, research, development	Policy	Not applicable	CPerMed provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation.
Pulpit	Co-funded by the EU	Multiple countries	Not applicable	–	ongoing	Patients, education, people engagement	Citizen and Patient engagement	Not applicable	The PULPIT project aims to revolutionize healthcare education by involving citizen patients in classroom activities and research at partner Higher Education Institutions (HEIs).
1+ Million Genomes (1+MG) / Framework	European Commission	Multiple countries	Not applicable	2018	ongoing	gene, genome, genotype, infrastructure	Genetic, clinical data	Not applicable	The 1+ Million Genomes (1+MG) initiative aims to enable secure access to genomics and the corresponding clinical data across Europe for better research, personalised healthcare and health policy making
EP PerMed	Co-funded by the EU	Multiple countries	Not applicable	2023	2033	Personalised medicine, funding	Other	Not applicable	The vision of the European Partnership for Personalised Medicine is to improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society.
European Alliance for Personalised Medicine (EAPM)	Private partners	Multiple countries	Not applicable	2012	ongoing	Personalised medicine	Policy	Not applicable	To improve patient care by accelerating the development, delivery and uptake of personalised medicine and earlier diagnostics, through consensus
The European Institute for Innovation through Health Data (i~HD)	Public and private entities	Multiple countries	Not applicable	2016	Ongoing	Data science	Big Data	Not applicable	Promote, develop and share good practices, tools and quality assessments to maximise community value from health data for innovations in health, care and research.
IMPaCT – Precision Medicine Infrastructure associated with Science and Technology	Coordinated and funded by ISCIII	Spain	National	2021	ongoing	Predictive medicine, Data, genomic medicine	Policy ;ELSA;Clinical studies;Citizen and Patient engagement;Biobanking;Health Technology Assesment;Drug and biomarkers discovery;	Not applicable	To establish the pillars to facilitate the effective deployment of Precision Medicine in the National Health System, ensuring scientific-technical quality, equity and efficiency in the use of the scientific resources available to respond to the needs of citizens. To become a scientific infrastructure of reference for the development of Precision Medicine in Spain in order to promote safer, more efficient, preventive and predictive medicine.
ATMP Sweden	Network	Sweden	National	–	ongoing	network, patients	Medicines	Not applicable	Accelerating patient access to safe and effective medicines based on recombinant genes, live cells and/or tissue engineering.
Genomics England	NHS	UK	Not applicable	2012	ongoing	genetics, genomics, infrastructure, data, personalised medicine	Other	Not applicable	Transforming healthcare, Accelerating research and Protecting citizens and leading the ethics debate

Cookies and Website Analysis

This list of projects and initiatives in personalised medicine is the output of a mapping activity that has involved all EP PerMed partners in a collective endeavour and represents a step forward in the rationalisation of initiatives on PM that are being carried out in the member states.